会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • QUINAZOLINE DERIVATIVE
    • 喹诺酮衍生物
    • WO1996033978A1
    • 1996-10-31
    • PCT/GB1996000959
    • 1996-04-23
    • ZENECA LIMITEDBARKER, Andrew, John
    • ZENECA LIMITED
    • C07D239/94
    • C07D239/94
    • The invention concerns derivatives of the formula (I), wherein n is 1, 2 or 3 and each R is independently halogeno; and R is amino-(2-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, pyrrolidin-1-yl-(2-4C)alkylamino, piperidino-(2-4C)alkylamino, morpholino-(2-4C)alkylamino, piperazin-1-yl-(2-4C)alkylamino or 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkylamino; or pharmaceutically acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
    • 本发明涉及式(I)的衍生物,其中n为1,2或3,并且每个R 2独立地为卤代; (2-4C)烷基氨基,(1-4C)烷基氨基 - (2-4C)烷基氨基,二 - [(1-4C)烷基]氨基 - (2-4C)烷基氨基, (2-4C)烷基氨基,哌啶子基 - (2-4C)烷基氨基,吗啉代 - (2-4C)烷基氨基,哌嗪-1-基 - (2-4C)烷基氨基或4-(1-4C)烷基哌嗪 -1-基 - (2-4C)烷基氨基; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物以及该化合物的受体酪氨酸激酶抑制性质用于治疗增殖性疾病例如癌症的用途。
    • 4. 发明申请
    • QUINAZOLINE DERIVATIVES
    • 喹诺酮衍生物
    • WO1996033977A1
    • 1996-10-31
    • PCT/GB1996000958
    • 1996-04-23
    • ZENECA LIMITEDBARKER, Andrew, John
    • ZENECA LIMITED
    • C07D239/94
    • C07D239/94
    • The invention concerns quinazoline derivatives of formula (I), wherein n is 1, 2 or 3 and each R is independently halogeno; and R is di-[(1-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy or 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
    • 本发明涉及式(I)的喹唑啉衍生物,其中n为1,2或3,并且每个R 2独立地为卤代; 并且R 1是二 - [(1-4C)烷基]氨基 - (2-4C)烷氧基,吡咯烷-1-基 - (2-4C)烷氧基,哌啶子基 - (2-4C)烷氧基,吗啉代 - 2-4C)烷氧基,哌嗪-1-基 - (2-4C)烷氧基或4-(1-4C)烷基哌嗪-1-基 - (2-4C)烷氧基; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物以及该化合物在治疗增殖性疾病如癌症中的受体酪氨酸激酶抑制性质的用途。
    • 7. 发明申请
    • QUINAZOLINE DERIVATIVES
    • 喹诺酮衍生物
    • WO1996016960A1
    • 1996-06-06
    • PCT/GB1995002768
    • 1995-11-28
    • ZENECA LIMITEDBARKER, Andrew, John
    • ZENECA LIMITED
    • C07D403/04
    • C07D231/12C07D233/56C07D249/08
    • The invention concerns quinazoline derivatives of formula (I) wherein m is 1 or 2; each R includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy; n is 1, 2 or 3; each R includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
    • 本发明涉及式(I)的喹唑啉衍生物,其中m为1或2; 每个R 1包括氢,卤代,(1-4C)烷基和(1-4C)烷氧基; n为1,2或3; 每个R 2包括氢,羟基,卤代和(1-4C)烷基; 并且Ar是含有至多四个氮杂原子的5-或9-元含氮连接的杂芳基部分,或Ar是含有至多三个氮杂原子的5-,6-,9-或10-元含氮连接的不饱和杂环部分 其具有一个或两个选自氧代和硫代的取代基; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物以及该化合物的受体酪氨酸激酶抑制性质用于治疗增殖性疾病例如癌症的用途。